Large-scale analyses in various cancers including patients with basal cell carcinoma and melanoma univocally reported that patients with intermediate to high mutational tumor burden assessed with next-generation sequencing (NGS) show a better clinical response to the PD-1/PD-L1 blockade [93,255,256]. Here, CD274 is linked to neoplasm.